Chronic Lymphocytic Leukemia (CLL) is a type of cancer that begins in the blood and affects the B lymphocytes or white blood cells that are part of the body’s immune system. Although in most cases the disease progresses slowly, in some cases it may need to be treated after diagnosis, and the treatments have changed much in recent years. Targeted treatments are increasingly used in the management of CLL and from the combinations of drugs developed to treat the cancer.
In the future, Ongoing research is evaluating ways to optimize current treatment approaches which will mean people are able to have treatment that is tailored to their needs, and it will help to, manage the disease treat side effects long term, and relapse.
Advances in Targeted Therapies for CLL
Many therapies are now available for the treatment of CLL patients. Importantly, the majority of them are targeted therapies, which means that they work on specific cells, by interfering with specific proteins or even pathways of the cancer cells and not on all cells. Importantly, most of them are not chemotherapeutic agents, thus they have a significantly different profile of action when compared to conventional chemotherapy.
BTK Inhibitors
BTK (Bruton’s tyrosine kinase) inhibitors are a class of cancer medicines that are used to treat CLL. They work by blocking a crucial signal required for cancer cells to survive. There are several licensed and investigational BTK inhibitors, such as ibrutinib, acalabrutinib and Zanubrutinib.
There are also ongoing research efforts to identify and explore the use of novel BTK inhibitors. A non-covalent BTK inhibitor, pirtobrutinib, is currently under investigation in a trial designed to treat patients with CLL or SM who have progressed on prior BTK inhibitor therapy. New treatments for CLL are being explored for use in patients who have relapsed into previous therapies and have limited alternative treatment options.
BCL-2 Inhibitors
BCL-2 inhibitors promote apoptosis in CLL cells. There is considerable data, in CLL clinical trials, concerning the use, either as a single agent or in combination with other classes of treatment for CLL patients. New studies are needed to explore the optimal use of BCL-2 inhibitors and to evaluate potential new combinations with existing therapy.
Future studies are also required to optimize the treatment duration as well as the combination of therapies and their sequence of application for individual groups of patients.
Fixed-Duration Treatment and Deeper Remissions
Fixed-duration treatment regimens are increasingly being evaluated and used in appropriate clinical settings. rather than continuing to take targeted therapies for an indefinite period of time, such as treatments combining a BTK inhibitor with BCL-2 inhibitor and antibody, like for example venetoclax-based regimens.
BCL-2 inhibitors are being combined with fixed-duration BTK-inhibitor regimens, as well as with immuno-therapies, within clinical trials to assess whether Clinical trials are evaluating whether these approaches may support longer remission periods and treatment-free intervals.
The Role of Minimal Residual Disease
To assess the level of cancer left after treatment, the amount of residual cancer is measured. Minimal residual disease (MRD) is the term used for the smallest amount of cancer that can be detected by a test using specialized machinery and typically samples blood or bone marrow (as is done for example in the Stella study).
Research is also needed to determine the optimal use of MRD-status information to establish the length of treatment, or to decide whether additional treatment is required.
Personalized Treatment for CLL
Cancer is different in every patient, and CLL is no exception. As research develops understanding of the disease, the treatments offered may become more individualized. There is no guarantee that every patient will receive a different drug, but their care will be tailored to their own circumstances and requirements.
Genetic and Molecular Testing
Tests that determine the TP53 mutation, FISH analysis and IGHV status of CLL can categorize the type of CLL a patient has and assist the treating doctor in determining the appropriate course of treatment for a patient with CLL taking into consideration the patient’s general health and other co-existing medical conditions.
Continuing research will uncover new markers to predict treatment outcomes and identify resistance. Current treatment selection may consider disease characteristics and patient-specific factors and overall health status to achieve disease management goals.
The use of the term “personalized treatment” does not mean everyone will be prescribed a different brand or type of drug. Rather, it encompasses the various factors that are currently utilized to make treatment decisions, including clinical information and molecular markers.
New Therapies for Treatment-Resistant CLL
As the number of treatments for CLL continues to expand, there will be cases of disease that are not optimally treated using currently available medicines. This may be the case after treatment with BTK inhibitors as well as with medicines from other classes such as the BCL-2 inhibitors. There are many emerging approaches to treat patients with CLL that have relapsed or are refractory to prior treatments.
Next-Generation Medicines
New types of treatments such as non-covalent BTK inhibitors, BTK degraders and others that attack CLL by different mechanisms are currently under investigation for relapsed/refractory disease. These investigational treatments are being evaluated in clinical studies for patients with relapsed or refractory CLL.
Immunotherapy and Cellular Therapies
Immunotherapy to induce a host immune response has also been studied as a therapeutic option in CLL, including bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies for patients with active against CLL cells or refractory/relapsed disease. These treatments represent investigational options that continue to be studied in appropriate patient populations.
Improving Safety and Long-Term Care
Future CLL research is designed not only to try to and treat cancer but also to manage the side effects of current CLL treatment and to improve patients’ quality of life whilst on treatment.
Some potential side effects of cancer treatment can cause serious problems for patients. Depending on the type of treatment used, CLL patients can experience problems such as serious infections, increased risk of bleeding, or cardiovascular events. Researchers are examining dose modifications, combination treatments, and treatment durations to better manage these potential side effects.
Even when treatment has led to remission it is still crucial to continue to monitor the patients in the long term. It may be necessary to adapt the treatment or to recognize progression of disease as well as treatment related complications.
The Importance of Clinical Trials
Clinical trials are a major component of CLL research to evaluate the effectiveness of new CLL treatments. Their goal is to assess whether a new treatment is more effective or tolerable than the currently used treatments, and often to establish a comparison to the established treatments. There are many clinical trials currently taking place to evaluate the use of new CLL treatments such as single agents and combination regimens for the treatment of newly diagnosed and relapsed CLL patients.
Conclusion
In the future more targeted and fixed-duration treatments will be introduced for CLL patients and for patients with newly diagnosed and relapsed CLL. Importantly there is much on-going research into BTK inhibitors, BCL-2 inhibitors, in immunotherapy as well as in cellular therapies for patients with CLL.
While new potential treatments are under investigation and show promise for the treatment of CLL patients, it is essential to remember that not all investigational treatments have proven to work for all patients and, thus, should only be used after a patient’s physician has reviewed evidence-based clinical information and discussed the potential treatment with the patient. It is crucial for more CLL treatments to be developed and for patients with CLL to be followed up for longer periods of time to determine the long-term effects of new treatments for CLL.
Disclaimer: The information provided in this article is intended for educational purposes only and should not be interpreted as medical advice, a clinical guideline, or a recommendation for any specific treatment.
